CEO Christopher Dawson and COO Andrew Galloway spent years working in clinical mental health treatment centers before betting big on psychedelics and ancient healing methods.
Two researchers argue we still can’t be sure what the effects of widespread public use of psychedelics would be, and point to possible negatives.
MindMed’s Interim CEO, Robert Barrow, has not made as many public appearances as opposed to MMED’s previous CEO, Jr Rahn.
As many of you know, almost two months ago, then MindMed’s CEO, JR Rahn, announced that he was stepping down, and he would be replaced immediately by Robert Barrow, then Chief Development Officer.
Since then, we have not had a lot of news from the company, and though we have heard from Barrow on previous Conference Calls, us the retail investors, have not had a chance to meet the man (at least digitally) as CEO yet.
That changed on August 3rd, when MNMD held a “fireside chat” over Zoom with Barrow, where we got to know him a little better, and he provided us with some new information.
In this video, we will play the most important clips and offer some commentary where necessary.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedStock #MNMD
August 4, 2021- This week’s Psychedelic Business News top stories…
“This designation not only expedites our regulatory, clinical, and product development plans but also validates our belief in the potential of ketamine,” says PharmaTher CEO Fabio Chianelli.
“Our app was designed with accessibility and ease of use as top priorities, so that psychedelic users in any state of mind can connect quickly with our diverse and compassionate peer support line volunteers,” says the nonprofit’s co-founder.
In today’s episode of the Psychedelic Spotlight podcast, we spotlight Dimensions Health Centers who are creating a new paradigm for hospitality by helping people to improve and transform their lives by drawing on the restorative power of nature, spa rituals, delicious food, and psilocybin-inspired ceremonies in safe, legal and luxurious settings.
As a result, the Canadian Psychedelic Association responds with a Memorandum of Regulatory Approval, which advises medicinal psilocybin therapy to be authorized in a safe and therapeutic environment.
“Based on our research, we think we’re able to get to psilocybin in fewer steps than any of the other published methods,” says the company’s CEO.
Psychae Institute will collaborate with other clinical research organizations to develop novel psychedelic medicines and accompanying psychotherapeutic treatment models.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.